HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Noom or its parent company. No affiliate links or compensation are involved.

Noom is one of many telehealth programs in the GLP-1 / weight management space. This editorial review covers Noom promo codes, discount offers, and eligibility rules currently visible on the brand's own site. Fair-balance editorial framing — not a buying recommendation. As of April 2026.

What Noom is

Noom (Noom, Inc.) operates as app-based subscription with medication add-on. Programs in this model typically include virtual clinical evaluation by a licensed provider, a written prescription to either a retail pharmacy (for FDA-approved brand products) or a 503A compounding pharmacy (for compounded semaglutide or tirzepatide), and ongoing follow-up. See Noom's official website for current program structure and pricing.

How Noom's program works

Most telehealth GLP-1 programs follow a similar structure: (1) patient fills out an intake form including weight, medical history, and medication list; (2) a licensed clinician reviews the intake and, if eligibility is met, issues a prescription; (3) the prescription is routed to either a retail pharmacy or a licensed compounding pharmacy for fulfillment; (4) ongoing telehealth follow-up supports dose titration and side-effect management. Variations exist in provider type (physician vs NP/PA), pharmacy partner (retail vs compounded), and subscription structure.

Pricing and access

Published pricing for Noom appears on the brand's own website. Program fees, medication costs, and total monthly spend vary by product (semaglutide vs tirzepatide vs other), subscription tier, and whether the brand dispenses FDA-approved brand products or compounded alternatives. Typical monthly totals in the telehealth GLP-1 market as of April 2026 fall between approximately $200 and $700+, with wide variance. Verify current pricing at Noom's official website before any commitment — numbers change frequently.

What the research shows on GLP-1 receptor agonists

The pharmacology of any legitimate GLP-1 program is driven by the underlying compound class: GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide). Key trial programs: STEP (semaglutide for weight management, published in The New England Journal of Medicine, 2021); SURMOUNT (tirzepatide for weight management, NEJM 2022); SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Trial populations and endpoints vary. Outcomes vary individually.

What's missing — the genetic variable no telehealth program addresses

No program like this one addresses the upstream genetic architecture that shapes every GLP-1 response. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene — the biological target of every GLP-1 compound), MC4R (a melanocortin receptor central to satiety and energy balance), and TCF7L2 (a transcription factor linked to glucose homeostasis and GLP-1 secretion) map the baseline metabolic terrain on which any GLP-1 compound operates. These variants are pathway-level. They do not predict response to any specific compound, but they do describe the biology a clinician is prescribing into — context that a telehealth prescription alone does not capture.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Not affiliated: PlexusDx is not affiliated with Noom and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1.

Disclaimer: This article is educational. PlexusDx is not affiliated with Noom and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols — semaglutide and tirzepatide with the genetic context most telehealth programs don't offer. Or start upstream: take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Is Noom a legitimate telehealth service?

Noom operates in the GLP-1 telehealth space as of April 2026. Legitimate GLP-1 telehealth programs share certain traits: licensed clinicians, state-licensed pharmacy partners, transparent pricing, and clinical evaluation before prescription. Verify credentialing and licensure on the brand's own site before any purchase decision.

How much does Noom cost?

Noom pricing is published on its own website and changes over time. Telehealth GLP-1 programs typically range $200–$700+ per month as of April 2026 depending on medication, subscription tier, and dispensing pathway. Verify current pricing on the brand's own site before any commitment.

Does genetic testing predict response to Noom's program?

No. The Precision Peptide Genetic Test does not predict response to any telehealth program or specific compound. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 biology — the upstream context that applies regardless of which telehealth service prescribes a compound.

How does PlexusDx compare to Noom?

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, paired with the Precision Peptide Genetic Test for upstream context. The differentiator is pathway-level genetic insight — context that most telehealth-only programs like Noom do not offer alongside the medication itself.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education